(MedPage Today) — BARCELONA — The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), demonstrating superiority over placebo for most of its endpoints, according to a presentation…
Source link : https://www.medpagetoday.com/meetingcoverage/eular/116082
Author :
Publish date : 2025-06-14 20:15:00
Copyright for syndicated content belongs to the linked Source.
